Overview

SWitching to Abilify Trial (SWAT)

Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy, safety and tolerance of an 12 and 26-week aripiprazole administration
Phase:
Phase 4
Details
Lead Sponsor:
Korea Otsuka Pharmaceutical Co., Ltd.
Treatments:
Aripiprazole
Olanzapine
Quetiapine Fumarate
Risperidone